Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biotechnol Prog ; 17(5): 897-906, 2001.
Article in English | MEDLINE | ID: mdl-11587582

ABSTRACT

This work investigates the utility of RPLC displacement chromatography for the purification of recombinant brain derived neurotrophic factor (rHu-BDNF) from its variants and E. coli. protein (ECP) impurities. The closely associated variants (six in total) differ by one amino acid from the native BDNF and thus pose a challenging separation problem. Several operational parameters were investigated to study their effects on the yield of the displacement process. The results indicated that the concentration of trifluoroacetic acid (TFA) in the buffer was a key factor in achieving the desired purification. Displacement chromatography on an analytical scale column resulted in extremely high purity and yield in a single chromatographic step. The process was successfully scaled-up with respect to particle and column diameter. The production rate of a pilot scale RPLC displacement process was shown to be 23 times higher than the combined production rates of the current preparative ion exchange and hydrophobic interaction gradient elution steps that are used to remove variant and ECP impurities, respectively.


Subject(s)
Brain-Derived Neurotrophic Factor/isolation & purification , Brain-Derived Neurotrophic Factor/pharmacology , Brain-Derived Neurotrophic Factor/standards , Cell Line , Cell Survival/drug effects , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , Humans , Quaternary Ammonium Compounds/chemistry , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology , Recombinant Proteins/standards , Trifluoroacetic Acid/chemistry
2.
Biotechnol Bioeng ; 68(6): 672-80, 2000 Jun 20.
Article in English | MEDLINE | ID: mdl-10799993

ABSTRACT

Displacement chromatography of proteins was successfully carried out in both hydrophobic interaction and reversed-phase chromatographic systems using low-molecular weight displacers. The displacers employed for hydrophobic displacement chromatography were water soluble, charged molecules containing several short alkyl and/or aryl groups. Spectroscopy was employed to verify the absence of structural changes to the proteins displaced on these hydrophobic supports. Displacement chromatography on a reversed-phase material was employed to purify a growth factor protein from its closely related variants, demonstrating the high resolutions that can be achieved by hydrophobic displacement chromatography. This process combines the high-resolution/high-throughput characteristics of displacement chromatography with the unique selectivity of these hydrophobic supports and offers the chromatographic engineer a powerful tool for the preparative purification of proteins.


Subject(s)
Chromatography/methods , Proteins/isolation & purification , Biotechnology , Brain-Derived Neurotrophic Factor/chemistry , Brain-Derived Neurotrophic Factor/isolation & purification , Chromatography, High Pressure Liquid , Humans , Indicators and Reagents , Molecular Weight , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification
3.
Arch Biochem Biophys ; 372(2): 248-60, 1999 Dec 15.
Article in English | MEDLINE | ID: mdl-10600162

ABSTRACT

The purpose of this work was the chemical characterization of variants of the recombinant human brain derived neurotrophic factor (rHu-BDNF), expressed in Escherichia coli. This paper also addresses the question of the in vitro activity of these variants. Chemical characterization of the variants employed peptide mapping using Glu-C protease and cyanogen bromide digestion on reduced and alkylated variants followed by the analysis of the digested peptides using mass spectrometry and Edman sequencing. The BDNF variants in this work have been designated by the order of their elution as observed from the high temperature RPLC assay. It was determined that Peaks 1 and 2, which eluted just before the predominant BDNF peak, had methionine sulfoxide instead of methionine at positions 31 and 61, respectively. Peak 4, which is chromatographically a single peak, contained three variants. Two of these variants had norleucine instead of methionine, at positions 61 and 92, respectively, while the third had methionine sulfoxide instead of methionine at position 92. Peak 5 had norleucine at position 31 instead of methionine. All of these variants showed in vitro biological activity consistent with the BDNF standard, suggesting the preservation of the trkB receptor-ligand binding domain of the variants.


Subject(s)
Brain-Derived Neurotrophic Factor/chemistry , Brain-Derived Neurotrophic Factor/metabolism , Genetic Variation , Alkylation , Binding Sites , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/pharmacology , Cell Line , Cell Survival/drug effects , Chromatography, High Pressure Liquid , Cyanogen Bromide/metabolism , Escherichia coli/genetics , Humans , Mass Spectrometry , Methionine/analogs & derivatives , Methionine/analysis , Molecular Weight , Norleucine/analysis , Oxidation-Reduction , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Peptide Mapping , Receptor, trkB/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Sequence Analysis, Protein , Serine Endopeptidases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...